Exagen Inc. (NASDAQ:XGN) Receives $12.50 Consensus Target Price from Analysts

Exagen Inc. (NASDAQ:XGN) has been given an average rating of “Moderate Buy” by the nine research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $12.50.

A number of analysts recently weighed in on XGN shares. Canaccord Genuity Group boosted their target price on Exagen from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Exagen in a report on Wednesday, January 21st. B. Riley Financial reaffirmed a “buy” rating and issued a $8.00 price objective (down previously from $18.00) on shares of Exagen in a research note on Friday, January 30th. Finally, BTIG Research lifted their target price on shares of Exagen from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, November 10th.

Exagen Stock Performance

NASDAQ XGN opened at $3.28 on Friday. Exagen has a 52-week low of $2.67 and a 52-week high of $12.23. The company has a debt-to-equity ratio of 1.35, a quick ratio of 4.08 and a current ratio of 4.08. The company has a market capitalization of $74.32 million, a P/E ratio of -3.57 and a beta of 1.90. The company has a fifty day moving average of $5.30 and a 200-day moving average of $8.24.

Institutional Investors Weigh In On Exagen

A number of hedge funds and other institutional investors have recently modified their holdings of XGN. Acadian Asset Management LLC bought a new position in Exagen during the 1st quarter worth approximately $25,000. Larson Financial Group LLC purchased a new stake in shares of Exagen during the third quarter valued at approximately $105,000. JPMorgan Chase & Co. grew its holdings in shares of Exagen by 320,280.0% in the third quarter. JPMorgan Chase & Co. now owns 16,019 shares of the company’s stock worth $176,000 after purchasing an additional 16,014 shares during the last quarter. R Squared Ltd purchased a new position in shares of Exagen in the fourth quarter worth $111,000. Finally, XTX Topco Ltd purchased a new position in shares of Exagen in the second quarter worth $133,000. Institutional investors own 75.25% of the company’s stock.

About Exagen

Exagen Inc is a molecular diagnostics company focused on improving the detection and management of autoimmune diseases. Headquartered in the United States, the company develops, manufactures and markets laboratory tests designed to help clinicians address diagnostic challenges associated with complex connective tissue disorders.

The company’s flagship product portfolio, marketed under the Avise® brand, includes multi-analyte assays such as the Avise® Connective Tissue Disease (CTD) panel, Avise® Lupus panel and Avise® Sjögren’s panel.